Target Information

Aortyx has successfully completed a €13.8 million Series A funding round, backed by various investors including Ship2B Ventures through the BSocial Impact Fund (supported by Banc Sabadell, EIF, and AXIS), Clave Capital, Nara Capital, and CDTI Innvierte, among others. Aortyx focuses on aortic dissection (AD), a severe and often fatal medical emergency where the inner layer of the aorta tears, leading to dangerous complications such as massive internal bleeding and organ failure.

AD currently affects over 50,000 individuals in Europe, and existing treatment options are limited and often ineffective. The prevalent treatments, which include open surgery and endovascular stenting, carry significant risks and can result in high mortality rates. Alternative medical therapies tend to be temporary solutions, failing to address the underlying issues long-term.

Industry Overview

The aortic dissection treatment landscape is complex and challenging. Open surgical repair, primarily for Type A aortic dissections (TAAD), is a highly invasive procedure associated with hospital mortality rates between 20% and 30%. For Type B dissections (TBAD), Thoracic Endovascular Aortic Repair (TEVAR) becomes a common choice, utilizing endovascular stents. However, TEVAR is not applicable to all patients and poses its own set of risks.

Furthermore, pharmacological treatment remains the go-to for many Type B patients, yet it yields a staggering five-year mortality rate of 50%. The inadequacy of current treatments highlights the pressing need for innovative solutions in the field of aortic dissection. Patients are often left without suitable options, necessitating a fresh approach to treatment.

Aortyx is positioned to address this gap in the market through its innovative medical technologies. Their product aims to provide a minimally invasive solution that has the potential to reduce the high mortality and complication rates associated with traditional treatments.

Internationally, the incidence of aortic dissection remains a worldwide concern, with a prevalence of 2 to 6 cases per 100,000 people each year. This highlights a significant global healthcare challenge that demands urgent attention and innovative treatment strategies.

Rationale Behind the Deal

The rationale behind Aortyx's funding round lies in its ambition to revolutionize the treatment of aortic dissection. With the raised capital, the company aims to initiate first-in-human trials within two years. The technological advancements associated with their steerable catheter device could drastically change the clinical approach to treating aortic dissections.

Historically, the challenging nature of AD treatments fosters high rates of risk and complications, which Aortyx seeks to mitigate. The development of a bioabsorbable patch that can be deployed through a catheter not only promises a minimally invasive option but also addresses significant shortcomings of existing solutions.

Information About the Investor

Ship2B Ventures is an investment firm dedicated to supporting solutions that provide transformative societal impacts through innovation. Their mission involves investing in organizations that address pressing social and environmental challenges while simultaneously contributing to economic growth.

Jordi Ferrer, Investment Director at Ship2B Ventures, recognized Aortyx’s potential to revolutionize cardiovascular medicine. He emphasized that, beyond the technical aspects of the product, Aortyx is driven by a social mission—a commitment to saving lives where current options are inadequate. Their backing of Aortyx underscores their confidence in the team's capabilities and vision.

View of Dealert

evaluar Aortyx's investment opportunity reveals a potentially game-changing entrant in the medical device industry. Their innovative approach presents significant advancements over traditional treatment methods for aortic dissection, suggesting that this investment could offer substantial returns, not only financially but also in terms of public health impact.

The success of Aortyx is rooted in its ability to address critical limitations of current therapies, attracting strong interest from both the medical community and investors. The expertise of the founding team is promising, further enhancing confidence in the execution of their vision.

If Aortyx successfully navigates the next phases of development and clinical trials, it could redefine the standard of care for aortic dissection, providing a safer option for high-risk patients. This potential for disruption within the healthcare system adds a layer of desirability for forward-thinking investors.

In conclusion, the investment in Aortyx is viewed favorably, given its potential to not only achieve significant returns but also save lives and improve healthcare outcomes on a global scale. The combination of an innovative product, strong leadership, and an acute awareness of market needs aligns well with the current trajectory of the healthcare technology landscape.

View Original Article